Fighting Osteoporosis With Risedronate Co-Therapy During Incretin (FORTIFY)
Bisphosphonate Co-Therapy to Preserve Musculoskeletal Health in Older Adults Using Tirzepatide
Tirzepatide produces rapid, clinically meaningful weight loss. In older adults, however, substantial weight reduction may accelerate loss of bone and muscle, increase frailty risk, and compound age-related skeletal vulnerability. The purpose of this study is to find out if taking risedronate along with tirzepatide preserves musculoskeletal health during tirzepatide-associated weight loss.
研究概览
地位
地位
干预/治疗
干预/治疗
详细说明
Tirzepatide produces rapid, clinically meaningful weight loss. Weight loss of this magnitude is accompanied by increased bone turnover, hip bone loss, and loss of fat-free mass. Risedronate is a bisphosphonate therapy that inhibits osteoclast-mediated bone resorption and has an established monthly oral regimen. Pilot bariatric-surgery data from the investigative team support feasibility [1], attenuation of bone loss and resorption [2], and a signal for preservation of appendicular lean mass [3]. This single-center, 12-month, randomized, double-blind, placebo-controlled, parallel-group phase 3 clinical trial evaluates the premise that risedronate will blunt the skeletal consequences of tirzepatide-associated weight loss and may secondarily preserve muscle through bone-muscle signaling pathways.
研究类型
研究类型
注册 (估计的)
注册
阶段
阶段
- 第三阶段
联系人和位置
学习联系方式
学习联系方式
- 姓名:Kim Kennedy
- 电话号码:336.713.8567
- 邮箱:Kimberly.Kennedy@Advocatehealth.org
学习地点
-
-
North Carolina
-
Winston-Salem、North Carolina、美国、27157
- Atrium Health Wake Forest Baptist
-
接触:
- Kim Kennedy
- 电话号码:336-713-8567
- 邮箱:Kimberly.Kennedy@Advocatehealth.org
-
-
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- BMI≥30 or 27.0-29.9 kg/m2 plus one weight related co-morbidity
- Weight stability (within 5% in past 3 months)
- Community dwelling
- English speaking
- Able to attend regular in person appointments, willingness to take tirzepatide and risedronate medication, and willing to provide informed consent
Exclusion Criteria:
- Weight >450 lbs (DXA limit)
- Disordered alcohol or substance use
- Eating disorder in past 5 years
- >1 fall (injurious or non-injurious) in past year or prior fragility fracture
- Osteoporosis (self-report, medication use, or T-score ≤ -2.5 on hip or spine DXA scan)
- Use of oral corticosteroids (>5 d/month in past 3 months), use of incretin analog (GLP1Ra or dual agonist) in past 24 months, use of any AOM or prescription osteoporosis medication in last 12 months, history of intolerance or adverse reaction to GLP1Ra (other incretin analog) or bisphosphonate, concomitant use of insulin secretagogues or insulin
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
手臂数量
武器和干预
参与者组/臂参与者组/臂 |
干预/治疗干预/治疗 |
|---|---|
|
实验性的:Tirzepatide Plus Risedronate
|
Tirzepatide 2.5 mg weekly for 4 weeks, then 5 mg, 7.5 mg, and 10 mg at 4-week intervals as tolerated; continue 10 mg weekly through month 12. Risedronate 150 mg orally once monthly for 12 doses |
|
有源比较器:Tirzepatide Plus Placebo
|
Tirzepatide 2.5 mg weekly for 4 weeks, then 5 mg, 7.5 mg, and 10 mg at 4-week intervals as tolerated; continue 10 mg weekly through month 12. risedronate matching placebo orally once monthly for 12 doses |
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Hip Bone Mineral Density
大体时间:from baseline to month 12
|
change in total hip areal bone mineral density by DXA |
from baseline to month 12
|
次要结果测量
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Appendicular Lean Mass
大体时间:Month 6, Month 12
|
appendicular lean mass by DXA |
Month 6, Month 12
|
|
Hip Bone Strength
大体时间:Month 6, Month 12
|
hip bone strength by QCT-derived finite element analysis |
Month 6, Month 12
|
|
Distal Tibia Trabecular Number
大体时间:Month 6, Month 12
|
distal tibia trabecular number by HR-pQCT |
Month 6, Month 12
|
|
Gait Speed
大体时间:Month 6, Month 12
|
fast-paced gait speed from the 400-m walk test |
Month 6, Month 12
|
合作者和调查者
调查人员
调查人员
- 首席研究员:Ashley Weaver, PhD、Atrium Health Wake Forest Baptist
研究记录日期
研究主要日期
学习开始 (估计的)
学习开始
初级完成 (估计的)
初级完成
研究完成 (估计的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
其他研究编号
- IRB00158768
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.